When developing innovative therapeutics, recruiting adequate numbers of suitable patients is undoubtedly a major cornerstone in a successful clinical trial. It is estimated that less than 10% of all clinical trials are completed on time and patient recruitment is considered to be the rate-limiting step. Inefficient adaptations by study sponsors, unrealistic and complex protocols as well as misinformed assessments of study sites are among the primary hurdles that hinder patient recruitment and retention. The prevalence and chronic nature of metabolic diseases has led investigators to explore solutions to the aforementioned problems as well as challenges that are unique to diabetes and obesity. Cultural differences and the demanding nature of long-term trials make patient retention an increased challenge in chronic diseases. Given the limited therapeutic targets for diabetes, there is also a shortage of absolutely novel antidiabetic drugs that can motivate patients to enroll on their own merit.
It is widely accepted that the traditional methods of patient recruitment and retention for diabetes trials are not sustainable in diverse and aging populations. The limited therapeutic targets for diabetes yields very few first-in-class drugs and this slows patient recruitment and keeps it competitive among trial sponsors. New outlooks and collaborations have to be explored to motivate patients to enroll and stay in the study. This one day event will highlight industry, regulatory, and patient perspectives in terms of what the biggest challenges are that hinder patient recruitment and retention in the metabolic disease field. Industry experts will talk about what a successful recruitment campaign should include as they reflect on some of the most successful and largest antidiabetic drug trials to date.
Why Attend? Discover the most efficient means of recruiting diabetic patients on a large multi-site scale by utilizing emerging methods.
Learn how new techniques and technology are improving patient retention for long-term trials.
Get perspectives from real patients and hear about what makes them enroll and stay in a study.
Understand the fundamental differences between recruiting for diabetes trials versus trials for other therapeutic areas.
Find out how cultural diversity can shape studies as experts share their experiences from the Middle East, Africa, Eastern Europe, and the Western World.
Who will benefit? Experienced executives from pharma, biotech, academia, and study directors involved in clinical trials for antidiabetic therapeutics and patient recruitment/ retention
VPs, professors, directors, and senior managers involved in clinical operations, clinical development, medical affairs
Agenda request To request the full agenda please follow the link:
http://www.nextlevelpharma.com/events/request_agenda/patient_recruitment_and_retention_for_diabetes_obesity_interventions
For Booking Information contact: Erika Vavrovicova
Tel: +421 232 660 382
Fax: +421 2 3301 0331
Email:
[email protected] Visit: www.nextlevelpharma.com
